Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoma | D008223 | — | C85.9 | 2 | 1 | — | — | — | 2 |
Sarcoma | D012509 | — | — | 1 | 1 | — | — | — | 1 |
Neuroblastoma | D009447 | EFO_0000621 | — | 1 | 1 | — | — | — | 1 |
Osteosarcoma | D012516 | — | — | 1 | 1 | — | — | — | 1 |
Ewing sarcoma | D012512 | EFO_0000173 | — | 1 | 1 | — | — | — | 1 |
Rhabdomyosarcoma | D012208 | — | — | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
Medical sociology | D012962 | — | — | 1 | — | — | — | — | 1 |
Drug common name | BIMIRALISIB |
INN | bimiralisib |
Description | Bimiralisib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform, serine/threonine-protein kinase mTOR, and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform. |
Classification | Small molecule |
Drug class | phosphatidylinositol 3-kinase (PI3K) inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Nc1cc(C(F)(F)F)c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cn1 |
PDB | — |
CAS-ID | 1225037-39-7 |
RxCUI | — |
ChEMBL ID | CHEMBL4084907 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 6Z3QHB00LB (ChemIDplus, GSRS) |